Subject Index

Notes
The abbreviation TDLUs in sub entries refers to terminal duct lobular units. Page numbers in bold refer to tables. Page numbers in italics refer to figures including those used in the examples.

A

Aberrations of Normal Development and Involution (ANDI) 17, 213
acinus
amorphous calcification 13, 30, 173
central necrosis 30
cystically dilated 213, 215, 242
distended 41, 173, 198
Grade 2 in situ carcinoma 112, 113, 145
involutorial type calcification 270
solid cell proliferation 30
amorphous calcifications in acinus 13, 30, 173
ductal distension 79, 80, 179
fibrocystic change 238, 240, 240, 241, 243, 258
in situ carcinoma 119, 131, 190
Grade 2 111, 117, 142
Grade 3 80, 185
intraluminal 29
lobular carcinoma in situ 152, 154
specimen radiography 208
subgross vs. conventional histology 15
terminology inconsistencies 17
vacuum-assisted biopsy 33
anti-actin staining
in acinus 17, 198

B

benign intraductal papilloma 84–89
blood vessels 163, 195, 196
bracketing technique 120, 189
branching calcifications 291
breast lump
casting type calcifications 86–89
hard 66–75
hormone replacement therapy and 170–175
mixed crushed–stone like and casting type calcifications 77–83
metastases 88, 175
pathological 86
auxiliary tail microcalcifications 38

C

calcifications
amorphous see amorphous calcifications
branching
broken needle tip–like 288, 290
casting type see casting type calcifications
cotton ball–like see powdery calcifications
crushed–stone like see crushed–stone like calcifications
differential diagnosis 211–303
dotlike 262, 274, 276, 277
involutorial type see involutorial type calcification
pleomorphic see pleomorphic calcifications
popcornlike 278
powdery see powdery calcifications
punctate 262, 274, 276, 277
round/oval 137
calcified hematoma 223
calcium oxalate crystals see wendelde crystals
cancerous ducts 178
casting type calcifications
characteristics 2
broken needle tip–like calcifications and 77, 78, 79, 177, 201, 201
diagnosis 2
disease progression 91
frequency of occurrence 3, 4
long-term outcome 306, 307
malignancy prediction 3, 5
malignancy ratio 5
palpable tumor 86
subgross/3D histology 89
central necrosis
distended acini 29
in situ carcinoma 71, 131, 190
Grade 2 33, 117
Grade 3 80
lobular carcinoma in situ 152, 154
terminal duct 173, 181
3D image 181
c-erbB-2/Her-2-neu staining 65
“close” surgical margin 101
cluster calcifications, necrotic malignant tissue 14
Cooper ligament infiltration 87
cotton ball–like calcifications see powdery calcifications
cribiform cell proliferation 218
cribriform in situ carcinoma 13, 80, 173
119, 131, 190
casting type calcifications and 291
crushed-stone like calcifications
benign 212
broken needle tip-shaped 122
casting type calcifications and 77, 78, 79, 177, 201, 201
characteristics 2
classification by malignant process 18–20
development 23
classification 2
technique comparison 14, 14–17
differential diagnosis 2, 211–303
diversity 103
fibroadenoma 291
follow-up period 10–14, 10–14
pitfalls 11
frequency of occurrence 3, 4
long-term outcome 306, 307
malignancy prediction 6, 161
mammography findings 8–14, 9
multiple clusters 93–206
de-novo 158
disease extent underestimation 20, 20, 93, 157–209, 158–209
intervening normal tissue 94–156
mammography-histology concordance 19, 19, 93, 94–156, 108, 109
no associated tumor mass 149
previously removed 118–123, 118–123, 125
one/two clusters 21–92
disappearance/decrease in number 43, 43–44
disease progression 42, 90–92
long-term outcomes 42–44, 42–45, 76–92, 76–92
mammography findings, disease extent underestimation 18, 18, 22, 46–92, 46–92
mammography-histology concordance 18, 18, 22, 24–44, 24–45
powdery calcifications and 19, 19, 112, 113, 145, 146
triangular arrowhead-shaped 98
work-up 10
CT, bone metastases 175
cystic hyperplasia see fibrocystic change cysts 225, 227
desmoplastic reaction 62, 63
neoductogenesis indicator 92, 169, 199
periductal 205, 207
Doppler ultrasound, one/two clusters 69, 63
dotlike (punctate) calcifications 262, 274, 276, 277
ductal carcinoma in situ (DCIS) 31, 65, 95
terminal duct changes 240, 241, 243, 258
ductectasia, fibrocystic change 216
ductile structures
conventional vs. subgross 3D histology 82
distended 92, 195, 196, 199
unnaturally concentrated 64, 65, 162, 194, 204
ducts, distended 51
papilloma 295
E

E-cadherin expression, lobular carcinoma in situ 152, 154
elbow sign 124
estrogen receptor expression, tumor 36
excessive intraductal component (EIC) 306

F

family history 164–169, 164–169
fascia infiltration, superficial 87
fibroadenoma 278–293
age and 278
calcifications
branching 291
broken needle–like 291
brushed–stone like 9
de-novo 286, 286–287
density 289
irregular 280, 281, 284
collagen fiber formation 279
diagnostic surgical biopsy 285, 285
differential diagnosis 278
epithelial component 279
frequency of occurrence 212, 218
in situ carcinoma containing 292
involution 278
large-bore needle biopsy 285
mammography vs. biopsy 285
menopausal women 278
natural history 278
stromal component 279, 279, 282, 287
treatment 287
fibrocystic change 213–261
bilateral extensive, with calcifications 226–231, 226–231
classification types 232–245
development 214
involutional type calcification 265
multiple clusters 182, 187, 202
neangiogenesis 187
one/two clusters 39, 57
palpable lesion 67, 68
papilloma 300
simple cyst 227
tortuous ducts 57
weddellite crystals 246

vacuum-assisted biopsy
amorphous calcifications 33
casting type calcifications 2
diagnostic value 2
fibroadenoma 288, 289
Grade 2 carcinoma in situ 40
multiple clusters 165, 127, 193, 203
necrosis 33
papilloma 297, 298, 299
solitary calcification group 40
vascular invasion 185

weddellite crystals 245, 245, 246, 247
diagnosis 245
fibrocystic change 238, 243, 244, 251, 259